214 Stock Overview
A clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Anebulo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$2.88 |
| 52 Week Low | US$1.40 |
| Beta | -1.01 |
| 11 Month Change | -18.39% |
| 3 Month Change | -22.83% |
| 1 Year Change | -25.26% |
| 33 Year Change | -75.73% |
| 5 Year Change | n/a |
| Change since IPO | -75.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 214 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | -25.3% | -20.1% | 8.2% |
Return vs Industry: 214 underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 214 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 214 volatility | |
|---|---|
| 214 Average Weekly Movement | 11.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 214's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 214's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3 | Richie Cunningham | www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Fundamentals Summary
| 214 fundamental statistics | |
|---|---|
| Market cap | €36.36m |
| Earnings (TTM) | -€7.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs 214 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 214 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.92m |
| Earnings | -US$7.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 214 perform over the long term?
See historical performance and comparison